Literature DB >> 22497528

Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients.

Sabine Breuer1, Margit Rauch, Susanne Matthes-Martin, Thomas Lion.   

Abstract

Viral infections after allogeneic hematopoietic stem cell transplantation (HSCT) are important complications associated with high morbidity and mortality. In this setting, reactivations of persisting latent viral pathogens from donor and/or recipient cells play a central role whereas the sterile environment of transplant units renders new infections less likely. The viruses currently regarded as most relevant in the HSCT setting include particularly the herpes virus family--specifically cytomegalovirus (CMV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6)--as well as human adenoviruses (AdVs) and the polyoma virus BK (BKV). Timely detection and monitoring of virus copy numbers are prerequisites for successful preemptive treatment approaches. Pre- and post-transplant surveillance by sensitive and quantitative molecular methods has therefore become an essential part of the diagnostic routine. In this review, we discuss diagnostic aspects and the clinical management of the most important viral infections in HSCT recipients, with a focus on pediatric patients.

Entities:  

Mesh:

Year:  2012        PMID: 22497528     DOI: 10.1007/BF03256431

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.476


  195 in total

1.  Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

Authors:  Karl S Peggs; Stephanie Verfuerth; Arnold Pizzey; Naeem Khan; Malcolm Guiver; Paul A Moss; Stephen Mackinnon
Journal:  Lancet       Date:  2003-10-25       Impact factor: 79.321

2.  Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection.

Authors:  A C Lankester; B Heemskerk; E C J Claas; M W Schilham; M F C Beersma; R G M Bredius; M J D van Tol; A C M Kroes
Journal:  Clin Infect Dis       Date:  2004-05-11       Impact factor: 9.079

3.  Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.

Authors:  P Ljungman; R de la Camara; C Cordonnier; H Einsele; D Engelhard; P Reusser; J Styczynski; K Ward
Journal:  Bone Marrow Transplant       Date:  2008-06-30       Impact factor: 5.483

4.  Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation.

Authors:  B Kampmann; D Cubitt; T Walls; P Naik; M Depala; S Samarasinghe; D Robson; A Hassan; K Rao; H Gaspar; G Davies; A Jones; C Cale; K Gilmour; M Real; M Foo; N Bennett-Rees; A Hewitt; P Amrolia; Paul Veys
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

5.  Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.

Authors:  Pierre Reusser; Hermann Einsele; John Lee; Liisa Volin; Montserrat Rovira; Dan Engelhard; Jürgen Finke; Catherine Cordonnier; Hartmut Link; Per Ljungman
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

6.  Postexposure prophylaxis of varicella in family contact by oral acyclovir.

Authors:  Y Asano; T Yoshikawa; S Suga; I Kobayashi; T Nakashima; T Yazaki; T Ozaki; A Yamada; J Imanishi
Journal:  Pediatrics       Date:  1993-08       Impact factor: 7.124

7.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

Authors:  Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

Review 8.  Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution.

Authors:  Julia A Brown; Vassiliki A Boussiotis
Journal:  Clin Immunol       Date:  2008-04-18       Impact factor: 3.969

9.  Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.

Authors:  Andreas Moosmann; Iris Bigalke; Johanna Tischer; Leah Schirrmann; Julitta Kasten; Stefanie Tippmer; Marina Leeping; Dusan Prevalsek; Gundula Jaeger; Georg Ledderose; Josef Mautner; Wolfgang Hammerschmidt; Dolores J Schendel; Hans-Jochem Kolb
Journal:  Blood       Date:  2010-01-26       Impact factor: 22.113

10.  Comparison of commercial and in-house Real-time PCR assays for quantification of Epstein-Barr virus (EBV) DNA in plasma.

Authors:  Francesca Perandin; Elisabetta Cariani; Caterina Patrizia Pollara; Nino Manca
Journal:  BMC Microbiol       Date:  2007-03-28       Impact factor: 3.605

View more
  13 in total

Review 1.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Point: is the era of viral culture over in the clinical microbiology laboratory?

Authors:  Richard L Hodinka
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

3.  Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy.

Authors:  Jeremy D Rubinstein; Xiang Zhu; Carolyn Lutzko; Tom Leemhuis; Jose A Cancelas; Sonata Jodele; Catherine M Bollard; Patrick J Hanley; Stella M Davies; Michael S Grimley; Adam S Nelson
Journal:  Blood Adv       Date:  2020-07-28

4.  Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients.

Authors:  Amy E Caruso Brown; Mindy N Cohen; Suhong Tong; Rebecca S Braverman; James F Rooney; Roger Giller; Myron J Levin
Journal:  Antimicrob Agents Chemother       Date:  2015-03-02       Impact factor: 5.191

5.  Human AdV-specific T cells: persisting in vitro functionality despite lethal irradiation.

Authors:  R Geyeregger; C Freimüller; J Stemberger; G Fischer; V Witt; G Fritsch
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

6.  The role of CD4(+) T cells in BKV-specific T cell immunity.

Authors:  B J D Weist; M Schmueck; H Fuehrer; A Sattler; P Reinke; N Babel
Journal:  Med Microbiol Immunol       Date:  2014-07-23       Impact factor: 3.402

7.  Broad-range PCR-electrospray ionization mass spectrometry for detection and typing of adenovirus and other opportunistic viruses in stem cell transplant patients.

Authors:  Jérôme Legoff; Linda Feghoul; Séverine Mercier-Delarue; Jean-Hugues Dalle; Catherine Scieux; Janine Chérot; Flore Sicre de Fontbrune; André Baruchel; Gérard Socié; François Simon
Journal:  J Clin Microbiol       Date:  2013-10-09       Impact factor: 5.948

8.  Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia.

Authors:  P Rujkijyanont; C Morris; G Kang; K Gan; C Hartford; B Triplett; M Dallas; A Srinivasan; D Shook; A Pillai; C-H Pui; W Leung
Journal:  Blood Cancer J       Date:  2013-08-30       Impact factor: 11.037

9.  Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry.

Authors:  Britta Eiz-Vesper; Britta Maecker-Kolhoff; Rainer Blasczyk
Journal:  Front Immunol       Date:  2013-01-28       Impact factor: 7.561

10.  Human adenovirus-specific γ/δ and CD8+ T cells generated by T-cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation.

Authors:  Jan Dörrie; Christian Krug; Christian Hofmann; Ina Müller; Verena Wellner; Ilka Knippertz; Stephan Schierer; Simone Thomas; Elke Zipperer; Dieter Printz; Gerhard Fritsch; Gerold Schuler; Niels Schaft; Rene Geyeregger
Journal:  PLoS One       Date:  2014-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.